GMS exhibited significantly higher accuracy compared to other variables, such as age, gender, drug type, the genomic mutation signature of immunotherapy for gastrointestinal tumors identified in previous studies (GIPS) (17), TMB, MSI, and PD-L1, across all three cohorts (Figures 3D–F). This evidence concerns the gene CD274 and digestive system neoplasm.